Correction to: Pre-emptive use of Sorafenib combined with DLI post HSCT in AML FLT3+: a single center experience
Bone Marrow Transplant
.
2021 Jun;56(6):1482.
doi: 10.1038/s41409-021-01242-9.
Authors
Antonella Bruzzese
1
2
,
Giovanni Manfredi Assanto
3
,
Daniela Diverio
3
,
Luisa Quattrocchi
3
,
Daniela Carmini
3
,
Ursula La Rocca
3
,
Maria Stefania De Propris
3
,
Silvia Maria Trisolini
3
,
Mattia Brescini
3
,
Giulia Galassi
3
,
Walter Barberi
3
,
Anna Paola Iori
3
Affiliations
1
Haematology, Department of Cellular Biotechnologies and Haematology, Sapienza University of Rome, Rome, Italy. antonellabruzzese@msn.com.
2
Department of Hematology/Oncology, Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Italy. antonellabruzzese@msn.com.
3
Haematology, Department of Cellular Biotechnologies and Haematology, Sapienza University of Rome, Rome, Italy.
PMID:
33637883
DOI:
10.1038/s41409-021-01242-9
No abstract available
Publication types
Published Erratum